Charles Schwab Investment Management Inc Phathom Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 264,494 shares of PHAT stock, worth $2.71 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
264,494
Previous 262,524
0.75%
Holding current value
$2.71 Million
Previous $2.4 Million
17.2%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding PHAT
# of Institutions
123Shares Held
54.7MCall Options Held
34KPut Options Held
58.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$104 Million5.64% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$76.5 Million20.79% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$35.8 Million2.73% of portfolio
-
Invesco Ltd. Atlanta, GA3.16MShares$32.4 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.75MShares$28.1 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $402M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...